Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Schrodinger reported revenue of $256M in the fiscal year ended Dec 2025, up 23.3% from the year before. Operating income was −$167M, an operating margin of −65.2%, and net income was −$103M. Operating cash flow of $14M less capital expenditure of $1M left free cash flow of $12M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 138 | 181 | 217 | 208 | 256 |
| Cost of revenue | 72.3 | 79.9 | 76.0 | 75.5 | 113 |
| Gross profit | 65.6 | 101 | 141 | 132 | 143 |
| Research & development | 90.9 | 126 | 182 | 202 | 173 |
| Selling, general & admin | 86.2 | 121 | 136 | 140 | 136 |
| Operating income | −111 | −147 | −177 | −209 | −167 |
| Pre-tax income | −101 | −149 | 42.9 | −186 | −102 |
| Income tax | 0.4 | 0.1 | 2.2 | 1.4 | 0.9 |
| Net income | −100 | −149 | 40.7 | −187 | −103 |
| Diluted EPS | −1.42 | −2.10 | 0.54 | −2.57 | −1.41 |
| Diluted shares | 70.6 | 71.2 | 75.0 | 72.7 | 73.4 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 120 | 90.5 | 155 | 147 | 231 |
| Receivables | 31.7 | 56.0 | 66.0 | 236 | 83.0 |
| Current assets | 625 | 534 | 568 | 635 | 519 |
| Net PP&E | 10.0 | 14.2 | 23.3 | 24.2 | 19.5 |
| Goodwill | 0.0 | 4.8 | 4.8 | 4.8 | 4.8 |
| Total assets | 756 | 689 | 803 | 823 | 726 |
| Payables | 8.1 | 9.5 | 16.8 | 10.7 | 11.5 |
| Deferred revenue | 55.4 | 57.9 | 56.2 | 112 | 113 |
| Current liabilities | 91.2 | 109 | 134 | 192 | 189 |
| Total liabilities | 199 | 241 | 254 | 402 | 362 |
| Shareholders' equity | 557 | 448 | 549 | 421 | 364 |
| Backlog (remaining obligations) | 26.7 | 20.2 | 36.4 | 59.5 | 240 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −70.7 | −120 | −137 | −157 | 13.9 |
| Capital expenditure | 7.2 | 8.0 | 13.4 | 7.3 | 1.4 |
| Free cash flow | −77.8 | −128 | −150 | −165 | 12.5 |
| Depreciation & amortisation | 2.8 | 4.3 | 5.6 | 6.2 | 6.0 |
| Stock-based compensation | 26.5 | 39.6 | 47.8 | 49.9 | 43.0 |
| Acquisitions | 0.0 | 6.4 | 0.0 | 0.0 | – |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 31.2% | 19.7% | −4.2% | 23.3% |
| EPS growth (YoY) | – | – | – | −575.9% | – |
| Gross margin | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| Operating margin | −80.8% | −81.1% | −81.9% | −100.8% | −65.2% |
| Net margin | −72.8% | −82.4% | 18.8% | −90.2% | −40.4% |
| Return on equityBlank when equity is negative | −18.0% | −33.3% | 7.4% | −44.4% | −28.4% |
| ROCEEBIT ÷ (assets − current liabilities) | −16.8% | −25.3% | −26.5% | −33.1% | −31.1% |
| Free cash flow margin | −56.4% | −70.6% | −69.3% | −79.3% | 4.9% |
| Cash conversion (CFO ÷ net income) | 0.70x | 0.80x | −3.36x | 0.84x | −0.13x |
| Receivable days | 84 | 113 | 111 | 415 | 118 |
| Payable days | 41 | 43 | 81 | 52 | 37 |
| Current ratio | 6.85x | 4.91x | 4.25x | 3.31x | 2.75x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.